219 related articles for article (PubMed ID: 24015339)
1. A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.
Channick RN; Frantz RP; Kawut SM; Palevsky H; Tumuluri R; Sulica R; Lauto PO; Benton WW; de Boisblanc B
Pulm Circ; 2013 Apr; 3(2):381-8. PubMed ID: 24015339
[TBL] [Abstract][Full Text] [Related]
2. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Verlinden NJ; Walter C; Raina A; Benza RL
J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
[TBL] [Abstract][Full Text] [Related]
3. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
Ataya A; Somoracki A; Cope J; Alnuaimat H
Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.
Preston IR; Feldman J; White J; Franco V; Ishizawar D; Burger C; Waxman AB; Hill NS
Pulm Circ; 2014 Sep; 4(3):456-61. PubMed ID: 25621159
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
Song C; Kunovszki P; Beaudet A
J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
[No Abstract] [Full Text] [Related]
6. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
Olschewski H; Walmrath D; Schermuly R; Ghofrani A; Grimminger F; Seeger W
Ann Intern Med; 1996 May; 124(9):820-4. PubMed ID: 8610951
[TBL] [Abstract][Full Text] [Related]
7. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
8. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
9. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.
Pan IZ; Carey JR; Jacobs JA; Dechand J; Sessions JJ; Sorensen T; Penn BA; Mayeux JD; Hatton ND; Ryan JJ
Front Med (Lausanne); 2020; 7():81. PubMed ID: 32296704
[No Abstract] [Full Text] [Related]
10. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case series and treatment protocol.
Coons JC; Miller T; Simon MA; Ishizawar DC; Mathier MA
Pulm Circ; 2016 Mar; 6(1):132-5. PubMed ID: 27162621
[TBL] [Abstract][Full Text] [Related]
11. Inhaled iloprost in pulmonary arterial hypertension.
Baker SE; Hockman RH
Ann Pharmacother; 2005; 39(7-8):1265-74. PubMed ID: 15976392
[TBL] [Abstract][Full Text] [Related]
12. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.
Ivy DD; Doran AK; Smith KJ; Mallory GB; Beghetti M; Barst RJ; Brady D; Law Y; Parker D; Claussen L; Abman SH
J Am Coll Cardiol; 2008 Jan; 51(2):161-9. PubMed ID: 18191742
[TBL] [Abstract][Full Text] [Related]
13. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
14. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
Ackerbauer KA; Tandon R
J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
Knudsen L; Schurawlew A; Nickel N; Tiede H; Ghofrani HA; Wilkens H; Ewert R; Halank M; Klose H; Bäzner C; Behr J; Hoeper MM
BMC Pulm Med; 2011 Dec; 11():56. PubMed ID: 22133492
[TBL] [Abstract][Full Text] [Related]
16. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group.
Olschewski H; Ghofrani HA; Schmehl T; Winkler J; Wilkens H; Höper MM; Behr J; Kleber FX; Seeger W
Ann Intern Med; 2000 Mar; 132(6):435-43. PubMed ID: 10733442
[TBL] [Abstract][Full Text] [Related]
17. Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension.
Raina A; Coons JC; Kanwar M; Murali S; Sokos G; Benza RL
Pulm Circ; 2013 Jan; 3(1):116-20. PubMed ID: 23662183
[TBL] [Abstract][Full Text] [Related]
18. Inhaled iloprost as an add-on therapy for advanced pulmonary arterial hypertension: An Indian perspective.
Bobhate P; Gupta RK; Karande T; Kulkarni S
Natl Med J India; 2022; 35(6):338-343. PubMed ID: 37167510
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
Ghofrani HA; Wiedemann R; Rose F; Olschewski H; Schermuly RT; Weissmann N; Seeger W; Grimminger F
Ann Intern Med; 2002 Apr; 136(7):515-22. PubMed ID: 11926786
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
